Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German Drug Report Could Mean More Pressure On Pharma Revenues

This article was originally published in The Pink Sheet Daily

Executive Summary

The annual German prescription report suggests an additional €4.6 billion can be cut from the country’s annual drug expenditures, which could cause the government to extend its temporary price moratorium and mandatory rebate, as well as pursue other cost-cutting measures.

You may also be interested in...



European Notebook: CHMP Opens Up A Bit; France Looks For $1B In Price Cuts; Spain Making Good On Pharma Debts

Europe's top scientific advisory panel, the CHMP, could reveal more of its thoughts on product approvals next year. French biopharma tries to stave off deep cuts in budgetary debate; Germany may consider more health reforms following recent elections; Invesco, Servier see exec changes

German Committee Prognosis Raises Pharma Hopes On Price Cap, Rebate

The positive financial prognosis for German health insurers might prompt the government to look at removing the drug price rise moratorium and obligatory rebate.

Evidence Growing That Drug Counterfeiters Are Targeting Generics In The EU

Counterfeit omeprazole has been found for the third time in Germany, suggesting that the generics sector must raise its game to combat this phenomenon.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel